- Status:
- Red
- Decision Date:
- May 2022
Comments
RED: NICE TA855 - Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NHSE commissioned. (Decision date - February 2023)Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again